AR067106A1 - Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina - Google Patents

Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina

Info

Publication number
AR067106A1
AR067106A1 ARP080102662A ARP080102662A AR067106A1 AR 067106 A1 AR067106 A1 AR 067106A1 AR P080102662 A ARP080102662 A AR P080102662A AR P080102662 A ARP080102662 A AR P080102662A AR 067106 A1 AR067106 A1 AR 067106A1
Authority
AR
Argentina
Prior art keywords
diseases
disorders
sirtuine
sirtuina
tiazol
Prior art date
Application number
ARP080102662A
Other languages
English (en)
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of AR067106A1 publication Critical patent/AR067106A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Los compuestos sirtuina-moduladores pueden ser usados para incrementar la duracion de la vida de una célula, y tratar y/o prevenir una amplia variedad de enfermedades y desordenes incluyendo , por ejemplo, enfermedades o desordenes relacionados al envejecimiento o el estrés, diabetes, obesidad, enfermedades neurodegenerativas enfermedad cardiovascular, desordenes de la coagulacion sanguínea, inflamacion, cáncer, y/o rubicundez, así como también enfermedades o desordenes que puedan beneficiarse de una incrementada actividad mitocondrial. También se proporcionan composiciones comprendiendo un compuesto sirtuina-modulador en combinacion con otro agente Reivindicacion 1: Un compuesto representado por la formula estructural (1): o una sal de ésta, donde: R es -H o -CH3; R1 es un grupo heterociclilmetil sustituido o no sustituido conteniendo es N; R2 es -H o -CH3; y R3 es un grupo piridil no sustituido.
ARP080102662A 2007-06-20 2008-06-20 Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina AR067106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663307P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
AR067106A1 true AR067106A1 (es) 2009-09-30

Family

ID=39810276

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102662A AR067106A1 (es) 2007-06-20 2008-06-20 Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina

Country Status (26)

Country Link
US (2) US7829556B2 (es)
EP (1) EP2167510B1 (es)
JP (1) JP5281081B2 (es)
KR (1) KR101525268B1 (es)
CN (1) CN101874031B (es)
AR (1) AR067106A1 (es)
AU (1) AU2008266746B2 (es)
BR (1) BRPI0813653A2 (es)
CA (1) CA2692099C (es)
CL (1) CL2008001821A1 (es)
CO (1) CO6261382A2 (es)
CR (1) CR11231A (es)
DO (1) DOP2009000283A (es)
EA (1) EA018182B1 (es)
ES (1) ES2534544T3 (es)
IL (1) IL202729A (es)
MA (1) MA31568B1 (es)
MX (1) MX2009013976A (es)
MY (1) MY149316A (es)
NZ (1) NZ581989A (es)
PE (1) PE20090423A1 (es)
TW (1) TW200918542A (es)
UA (1) UA104127C2 (es)
UY (1) UY31170A1 (es)
WO (1) WO2008156866A1 (es)
ZA (1) ZA200908882B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US20070092577A1 (en) * 2005-10-03 2007-04-26 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
KR20110007235A (ko) * 2008-05-01 2011-01-21 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 퀴놀린 및 관련 유사체
KR20110036602A (ko) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체
SG196775A1 (en) 2008-09-29 2014-02-13 Sirtris Pharmaceuticals Inc Chromenone analogs as sirtuin modulators
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
CA2746506A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
PE20120057A1 (es) 2008-12-19 2012-02-24 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
AU2010258792B2 (en) 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
WO2011130595A2 (en) 2010-04-15 2011-10-20 Sirtris Pharmaceuticals, Inc. Sirtuin activators and activation assays
WO2011139387A1 (en) * 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011143317A2 (en) * 2010-05-11 2011-11-17 President And Fellows Of Harvard College Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
CN103619405B (zh) 2011-05-09 2015-11-25 赛博恩特医疗器械公司 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015002892A1 (en) * 2013-07-01 2015-01-08 Meier Joshua Abraham Methods of treating diseases by modulating mitochondrial dna deletions
EP3110507B1 (en) 2014-02-27 2020-11-18 NuSirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
RU2016149764A (ru) 2014-06-02 2018-07-17 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Получение и применение кристаллического бета-d-никотинамида рибозида
KR20170008320A (ko) 2014-06-06 2017-01-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
KR101839688B1 (ko) 2015-08-21 2018-03-19 중앙대학교 산학협력단 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017123161A1 (en) * 2016-01-15 2017-07-20 Agency For Science, Technology And Research Inhibition of intracellular growth of mycobacterium species and its applications
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017147180A1 (en) 2016-02-22 2017-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
EP3668402A4 (en) 2017-08-14 2021-05-19 Setpoint Medical Corporation VAGUS NERVOUS STIMULATION PRE-SCREENING TEST
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN109700790A (zh) * 2018-12-28 2019-05-03 中南大学湘雅医院 一种靶向AQP3的抗皮肤衰老药物Butein
CN111000854B (zh) * 2019-12-30 2023-06-09 昆药集团股份有限公司 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2023244862A1 (en) * 2022-06-17 2023-12-21 Codagen Biosciences, Inc. Sirtuin modulating compounds, including sirtuin activating compounds, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
US3517007A (en) 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
ZA735753B (en) 1972-09-14 1974-07-31 American Cyanamid Co Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles
US4018932A (en) 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
JPH0576084A (ja) 1991-09-11 1993-03-26 Matsushita Electric Ind Co Ltd 遠隔表示装置
JPH05289689A (ja) 1992-04-06 1993-11-05 Sanyo Electric Co Ltd 可搬性規則音声合成装置
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
CN1638765A (zh) 2001-07-27 2005-07-13 柯里斯公司 Hedgehog信号转导途径介质、其相关组合物以及应用
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2005298333A (ja) 2001-11-15 2005-10-27 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
CA2517720A1 (en) 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
WO2004080481A1 (en) 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
JP2007516982A (ja) 2003-12-15 2007-06-28 日本たばこ産業株式会社 シクロプロパン化合物及びその医薬用途
AU2005207029B2 (en) 2004-01-20 2011-09-01 Brigham Young University Novel sirtuin activating compounds and methods for making the same
RU2445095C2 (ru) 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
PT3006040T (pt) * 2004-06-04 2018-03-28 Univ Washington Métodos e composições para o tratamento de neuropatias
CA2586870A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
EA200702445A1 (ru) 2005-05-09 2008-04-28 Ачиллион Фармасьютикалз, Инк. Соединения тиазола и способы их применения
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
KR20100086498A (ko) 2007-11-08 2010-07-30 서트리스 파마슈티컬즈, 인코포레이티드 가용화된 티아졸로피리딘
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
CL2008001821A1 (es) 2009-03-13
UA104127C2 (en) 2014-01-10
US20090012080A1 (en) 2009-01-08
UY31170A1 (es) 2009-01-30
US7829556B2 (en) 2010-11-09
MA31568B1 (fr) 2010-08-02
US8247565B2 (en) 2012-08-21
JP5281081B2 (ja) 2013-09-04
WO2008156866A1 (en) 2008-12-24
AU2008266746A1 (en) 2008-12-24
CA2692099A1 (en) 2008-12-24
US20110015192A1 (en) 2011-01-20
CR11231A (es) 2012-05-16
CN101874031B (zh) 2013-02-20
IL202729A (en) 2013-10-31
BRPI0813653A2 (pt) 2014-12-30
ES2534544T3 (es) 2015-04-24
EA018182B1 (ru) 2013-06-28
EP2167510A1 (en) 2010-03-31
TW200918542A (en) 2009-05-01
DOP2009000283A (es) 2011-03-31
CO6261382A2 (es) 2011-03-22
EP2167510B1 (en) 2015-02-25
KR101525268B1 (ko) 2015-06-02
JP2010530431A (ja) 2010-09-09
MX2009013976A (es) 2010-04-27
MY149316A (en) 2013-08-30
EA201070034A1 (ru) 2010-06-30
IL202729A0 (en) 2010-06-30
CN101874031A (zh) 2010-10-27
CA2692099C (en) 2016-08-09
NZ581989A (en) 2012-06-29
AU2008266746B2 (en) 2012-03-15
PE20090423A1 (es) 2009-04-18
ZA200908882B (en) 2010-08-25
KR20100038093A (ko) 2010-04-12

Similar Documents

Publication Publication Date Title
AR067106A1 (es) Derivados de imidazo[2,1-b]tiazol moduladores de sirtuina
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
AR067107A1 (es) Derivados de tiazol[5,4-b]piridin moduladores de sirtuinas
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
WO2008073451A8 (en) Benzoimidazole derivatives as sirtuin (sir) modulating compounds
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
EA201071263A1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
PE20120668A1 (es) Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa
EA201170137A1 (ru) Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
EA201070579A1 (ru) Солюбилизированные тиазолопиридины
WO2010037127A8 (en) Chromenone analogs as sirtuin modulators
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
AR061500A1 (es) Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
CL2008003153A1 (es) Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BR112014003704A2 (pt) moduladores ror gama
Xin et al. Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke
AR054220A1 (es) 5-fenilpirimidinas i sustituidas, composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
DOP2006000146A (es) Amidas sustituidas con heteroarilos que comprenden un grupo enlazador saturado, y su uso como agentes farmaceúticos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure